Navigation Links
Mylan Launches First Generic Version of Vfend® Tablets

PITTSBURGH, Feb. 15, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Voriconazole Tablets, 50 mg and 200 mg, under a previously announced settlement and license agreement with Pfizer Inc. Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Voriconazole Tablets and was awarded 180 days of marketing exclusivity.  

Voriconazole Tablets are the generic version of Pfizer's Vfend® Tablets, a triazole antifungal agent. This product had U.S. sales of approximately $186 million for the 12 months ending Dec. 31, 2010, according to IMS Health.

Currently, Mylan has 170 ANDAs pending FDA approval representing $97.7 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $24.2 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit For more information about generic drugs, please visit

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Receives Approval for First-to-File Generic Sular® Extended-Release Tablets
2. Mylans Matrix Obtains License for Promising HIV/AIDS Treatment
3. Mylan Announces Lipitor® Settlement Agreement
4. Mylan Announces Caduet® Settlement Agreement
5. Mylans Matrix Receives Approval for Generic Version of Protonix® Delayed-release Tablets
6. Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Lamivudine and Zidovudine Tablets, 30 mg/60 mg
7. Mylan Receives Approval for Generic Version of Precose® Tablets
8. Mylan Announces Voluntary De-listing of 1.25% Senior Convertible Notes Due 2012 from Nasdaq
9. Mylans Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe
10. Mylan Confirms First-to-File Patent Challenge Relating to Orapred ODT®
11. Mylan Receives Approval for Generic Version of Adalat® CC Tablets
Post Your Comments:
(Date:11/24/2015)... --  HeartWare International, Inc . (NASDAQ: HTWR ), ... that are revolutionizing the treatment of advanced heart failure, ... Doug Godshall is scheduled to present at the ... December 1, 2015 at 3:00 p.m. ET.  The conference ... York . .  A ...
(Date:11/24/2015)... F1000Workspace - a research collaboration, reference management ... just six months ago. --> F1000Workspace - ... - since it was launched just six months ago. ... F1000Workspace - a research collaboration, reference management and ... six months ago. --> --> ...
(Date:11/24/2015)... , Nov. 24, 2015 iRhythm Technologies, Inc. ... cardiac care, today announced that it will participate in the 27th ... in New York, NY . Kevin ... on Tuesday December 1, 2015 at 8:50am ET. ... . --> . --> ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... The ... comes to several aspects of orthopedic care. They have received recognition for excellence ... general orthopedic care. , Becker's Hospital Review selected hospitals for inclusion based ...
(Date:11/24/2015)... Salt Lake City, UT (PRWEB) , ... November 24, 2015 , ... ... according to Forbes Magazine. For a business, it is critical that the first impression ... of a business, they are not likely to buy anything or want to return. ...
(Date:11/24/2015)... ... November 24, 2015 , ... Brillouin Energy ... Brillouin is the developer of renewable energy technologies capable of producing commercially useful ... announced today that its WET™ and HHT™ Boiler System reactor core modules were ...
(Date:11/24/2015)... ... November 24, 2015 , ... United Benefit ... welcome Winter-Dent & Company as its newest Partner Firm. Based in Jefferson City, ... client's most trusted advisor regardless of whether that client is a business, a ...
(Date:11/24/2015)... ALEXANDRIA, VA (PRWEB) , ... November 24, 2015 ... ... encourages people across the United States to support their local poison centers through ... been designated as #GivingTuesday: calls it “a day that inspires people to ...
Breaking Medicine News(10 mins):